CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 40 enrolled
Drug / intervention
BMS-813160 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03496662
NCT03496662Phase 2Completed
CompareCT.gov

A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC)

Washington University School of Medicine·interventional·Posted Apr 12, 2018·Updated Jul 29, 2025

In Brief

A Phase 2 clinical trial evaluating BMS-813160, Nivolumab, and 4 other interventions for Pancreatic Ductal Adenocarcinoma. Completed, enrolled 40 participants across 1 site.

Detailed Summary

The purpose of this research study is to learn more about a new combination of drugs being given to treat pancreatic cancer. The drugs being tested are BMS-813160, nivolumab, gemcitabine, and nab-paclitaxel. The investigators will be looking at both the side effects and the way the disease responds to treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPancreatic Ductal Adenocarcinoma
CountriesUnited States
CollaboratorsBristol-Myers Squibb, The Foundation for Barnes-Jewish Hospital, National Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedApr 12, 2018
Enrollment StartAug 31, 2018
Primary CompletionOct 28, 2021
Study CompletionJul 25, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 8.2 years ago

Interventions

BMS-813160drug

BMS-813160 will be supplied by Bristol Myers Squibb

Nivolumabdrug

Nivolumab will be supplied by Bristol Myers Squibb

Gemcitabinedrug

Gemcitabine will be given as per routine care from commercial supply.

Nab-paclitaxeldrug

Nab-paclitaxel will be given as per routine care from commercial supply.

Biopsyprocedure

Pre-treatment, end of cycle 2, end of treatment for patients who progress or otherwise do not go to surgery, and surgery for patients who do go to surgery

Peripheral bloodprocedure

-Cycle 1 Day 1 before treatment begins, after 2 cycles of treatment +/- 3 days of mandatory tumor biopsy, end of treatment for patients who progress or otherwise do not go to surgery, and no more than 24 hours prior to time of surgery (if applicable)